Myopia News and Research

RSS

Myopia, also called nearsightedness or shortsightedness, is a refractive defect of the eye in which collimated light produces image focus in front of the retina when accommodation is relaxed.

Presence of myopia significantly affects muscles used in focusing lens of the eye

The presence of myopia, or nearsightedness, significantly affects the muscles used in focusing the lens of the eye--a finding with important implications for the development of "accommodating" implanted intraocular lenses (IOLs) that can adjust to different visual distances, reports a study in the January issue of Optometry and Vision Science, official journal of the American Academy of Optometry.

29 Dec 2015

Up to 1 billion people could be at risk of going blind by 2050, say researchers

Up to 1 billion people could be at risk of blindness by the middle of the century if an emerging short-sightedness (myopia) epidemic is ignored say researchers at the Brien Holden Vision Institute.

8 Oct 2015

Spending more time outdoors may prevent short-sightedness in children

Adding an extra 40 minutes of outdoor activity to children’s usual time outdoors reduced the incidence of myopia over a three year period, providing the first indicator that myopia may actually be preventable.

17 Sep 2015

CUMC vision researchers discover gene that causes myopia

Vision researchers at Columbia University Medical Center have discovered a gene that causes myopia, but only in people who spend a lot of time in childhood reading or doing other "nearwork."

1 Sep 2015

Laser eye surgery: a glimpse into the future - An interview with Professor Dan Reinstein

LASIK (Laser In Situ Keratomileusis) creates a hinged flap with a microkeratome and evaporating corneal tissue under the flap with an excimer laser. However, the concept that refractive error could be corrected by sculpting corneal stromal tissue to change corneal curvature was the brainchild of Jose Ignacio Barraquer Moner in 1948.

9 Aug 2015

Myopia on the rise across Europe, new study finds

Myopia or short-sightedness is becoming more common across Europe, according to a new study led by King's College London. The meta-analysis of findings from 15 studies by the European Eye Epidemiology Consortium found that around a quarter of the European population is short-sighted but it is nearly twice as common in younger people, with almost half (47 per cent) of the group aged between 25 and 29 years affected.

12 May 2015

Report describes effectiveness of new computer-based vision-screening test for kids

Many eye disorders in young children are asymptomatic and may remain undetected without testing. Since effective treatments are available for many of those conditions, early identification and intervention are critical to prevent potentially permanent vision problems.

29 Apr 2015

Looking for standardized approach to testing twilight vision

A simple method of testing "twilight vision" gives reliable results in identifying people who have decreased visual acuity under low light conditions, according to a study in the May issue of Optometry and Vision Science, official journal of the American Academy of Optometry.

25 Apr 2015

Study identifies single test that can predict onset of myopia in children

A study of 4,500 U.S. children over 20 years has identified a single test that can predict which kids will become nearsighted by the eighth grade: a measure of their current refractive error.

3 Apr 2015

Orthokeratology technique slows progression of myopia in children

A technique called orthokeratology ("Ortho-K")--using custom-made contact lenses to shape the growing eye--has a significant effect in slowing the progression of myopia (nearsightedness) in children, according to a research review in the March issue of Optometry and Vision Science, official journal of the American Academy of Optometry.

25 Feb 2015

$Scleral imbrication shows promise in second surgery for refractory MHRD$

Scleral imbrication shows promise in second surgery for refractory MHRD

Combining vitrectomy and gas tamponade with sclera imbrication results in high retinal reattachment and macular hole closure rates among patients with refractory macular hole retinal detachment associated with high myopia, study findings indicate.

13 Feb 2015

Study: Lower-income students in China have better vision compared to middle-class counterparts

In one of the largest population-based studies ever conducted on nearsightedness in children, researchers have discovered that lower-income students in China have better vision than their middle-class counterparts. Data show that nearsightedness, also called myopia, is twice as prevalent in the middle-income province of Shaanxi compared to the poorer neighboring province of Gansu.

5 Feb 2015

Health Canada approves Lucentis (ranibizumab) for myopic CNV

Novartis Pharmaceuticals Canada Inc. announced today that Lucentis (ranibizumab), the treatment for several major causes of vision loss, has been approved by Health Canada for the treatment of visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).

8 Oct 2014

New approach to measuring, correcting visual abnormalities

A technique developed by astronomers seeking a clear view of distant objects in space is being intensively studied as a new approach to measuring and correcting visual abnormalities.

25 Sep 2014

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).

22 Sep 2014

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema.

11 Aug 2014

Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

31 Jul 2014

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

29 Jul 2014

Study shows correlation between education and nearsightedness

Education and behavior have a greater impact on the development of nearsightedness than do genetic factors: With each school year completed, a person becomes more nearsighted.

22 Jul 2014

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.

18 Jul 2014